Rindopepimut

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine ^[1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. ^[2]

The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope ^[3] ) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). ^[4]

The US FDA granted it Breakthrough Therapy designation for glioblastoma in Feb 2015 meaning that it might be able to get approval sooner if it is effective. ^[5]

Clinical trials

Glioblastoma

The phase II ACT III study reported encouraging results in June 2015. ^[1]

The ReACT clinical trial for glioblastoma reported encouraging results in 2015. ^[2]

In March 2016 the phase III ACT IV trial ^[6] was terminated because it did not increase overall survival. ^[7]

References

1. Zussman; et al. (2015). "Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma". Neurosurgery. 76 (6): N17. doi: 10.1227/01.neu.0000465855.63458.0c . PMID   25985004.
2. Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows. WSJ Nov 2015
3. "FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma. Feb 2015". Archived from the original on 2016-05-05. Retrieved 2016-04-18.
4. rindopepimut definition
5. Khleif, Samir N.; Rixe, Olivier; Skeel, Roland (2016). Skeel's Handbook of Cancer Therapy. Lippincott Williams & Wilkins. ISBN   9781496353399.
6. Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)
7. "Rindopepimut Misses OS Endpoint in Phase III Glioblastoma Trial. March 2016". Archived from the original on 2016-05-05. Retrieved 2016-04-18.